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Base excision repair (BER) pathway executed by a complex network of proteins is the major 
system responsible for the removal of damaged DNA bases and repair of DNA single strand 
breaks (SSBs) generated by environmental agents, such as certain cancer therapies, or arising 
spontaneously during cellular metabolism. Both modified DNA bases and SSBs with ends oth-
er than 3’-OH and 5’-P are repaired either by replacement of a single or of more nucleotides 
in the processes called short-patch BER (SP-BER) or long-patch BER (LP-BER), respectively. In 
contrast to Escherichia coli cells, in human ones, the two BER sub-pathways are operated by 
different sets of proteins. In this review the selection between SP- and LP-BER and mutations 
in BER and end-processors genes and their contribution to bacterial mutagenesis and human 
diseases are considered.
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INtRODuctION
Living organisms are continuously exposed 
to damaging agents both from the environment and 
from endogenous metabolic processes, whose action 
results in modification of proteins, lipids, carbohy-
drates and nucleic acids. Events that lead to DNA 
modification include radiation, hydrolysis, exposure 
to reactive oxygen or nitrogen species and other re-
active agents, like alkylating agents and lipid per-
oxidation products (Lindahl, 1993; Tudek et al., 2006; 
Olinski et al., 2007; Tudek, 2007). To counteract these 
threats organisms are equipped with multiple dam-
age prevention and repair systems to ensure the sta-
bility of DNA and to protect the genome from po-
tential mutagenic modification and allow accurate 
transmission of genetic information.
The knowledge of DNA repair processes is 
critical to our understanding of how and why the 
genome is affected during the lifespan of the or-
ganism, and how the DNA, RNA and nucleotide 
repair systems efficiently work via several different 
pathways, such as: (1) sanitization of the nucleotide 
pool (for more details see accompanying review by 
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Arczewska & Kusmierek, this issue), (2) direct rever-
sion of base modifications by (i) demethylation proc-
esses (for more details see accompanying review by 
Nieminuszczy & Grzesiuk, this issue) and (ii) by 
6–4 photolyase or CPD photolyase (Kim et al., 1994; 
Sancar, 1994), or (3) excision of (i) misincorporated 
bases in the newly replicated DNA strand by mis-
match repair (MMR) (for more details see accompa-
nying review by Arczewska & Kusmierek, this is-
sue), (ii) excision of bulky damage from both DNA 
strands or from the transcribed strand by nucleotide 
excision repair (NER) (for more details see accom-
panying review by Maddukuri et al., this issue), and 
(iii) excision of oxidized, methylated or misincorpo-
rated bases from DNA by base excision repair (BER) 
which is described in more details in this review. 
Damaged bases are also a source of the single strand 
breaks (SSBs) and double strands breaks (DSBs). 
SSBs repair (SSBR) is also discussed in this review. 
The strand breaks are subject to recombinational 
repair (for more details see accompanying review 
by Nowosielska, this issue). Despite the protection 
provided by these mechanisms some of the damage 
escapes repair. Unrepaired DNA damage may block 
replication and engage alternative DNA polymer-
ases in the process of so-called translesion synthesis 
(TLS) to by-pass the lesion in an error-free or er-
ror-prone fashion (reviewed by: Bebenek & Kunkel, 
2004; Shcherbakova & Fijalkowska, 2006). To sum 
up, the unrepaired DNA damage leads to replica-
tion and transcription errors and in consequence to 
mutagenesis, ageing and various diseases, including 
carcinogenesis and neurodegeneration (reviewed by: 
Krokan et al., 2004; Bartsch & Nair, 2006).
PROcESSES LEADINg tO DNA BASE 
MODIfIcAtIONS
DNA base modifications are formed by both 
exogenous (i.e. environmental) and endogenous fac-
tors. Endogenous DNA damage occurs at a high fre-
quency compared with exogenous damage and the 
types of damage produced by normal cellular proc-
esses are identical or very similar to those caused 
by some environmental agents (Jackson & Loeb, 
2001). It has been proposed that the DNA damage 
from endogenous sources gives rise to 20 000 le-
sions per mammalian cell per day, most of the le-
sions being deaminations, spontaneous hydrolysis of 
the N-glycosidic bond, alkylations, and damage by 
reactive oxygen or nitrogen species and lipid peroxi-
dation products (Lindahl, 1993; Drablos et al., 2004; 
Tudek et al., 2006; Olinski et al., 2007). Lesions are 
also caused by errors in DNA metabolism, including 
the formation of SSBs and DSBs from the collapse 
of replication forks and the introduction of modified 
nucleic acid bases during DNA replication. Exam-
ples of base modifications discussed below and re-
paired by BER are shown in Fig. 1.
Deamination of DNA bases
DNA bases containing an exocyclic amino 
group, namely adenine (A), guanine (G), cytosine 
(C), and 5-methylcytosine (5-meC) are susceptible 
to spontaneous hydrolytic deamination to hypoxan-
thine (Hyx), xanthine (X), uracil (U), and thymine 
(T), respectively. Deamination occurs more frequent-
ly in single-stranded than in double-stranded DNA, 
where the amino groups are protected by participat-
ing in hydrogen bonds (Lindahl, 1993). Spontaneous 
deamination is rather slow, but it can be significant-
ly accelerated in vivo by nitrogen dioxide (NO2) and 
dinitrogen trioxide (N2O3) formed during inflamma-
tion or by UV- as well as by γ-irradiation (reviewed 
by: Kavli et al., 2007).
Loss of DNA bases via N-glycosidic bond  
hydrolysis
The N-glycosidic bond between base and 
deoxyribose in DNA can be hydrolyzed spontane-
ously or by DNA N-glycosylases during removal 
of damaged or incorrect bases from DNA by BER. 
This process leads to formation of an apurinic/apy-
rimidinic (AP) site (AP-site). Additionally, reactive 
oxygen species (ROS) and alkylating agents pro-
mote the release of bases, often by introducing le-
sions that destabilize the N-glycosidic bond (Lin-
dahl, 1993; Guillet & Boiteux, 2003). AP-sites are 
among the most frequent endogenous lesions found 
in DNA and about 10 000 lesions are formed per hu-
man cell per day (Lindahl, 1993). Purines are lost at 
a rate 500 times higher than pyrimidines, and the 
depurination rates of A and G are comparable (Loeb 
& Preston, 1986). AP-sites are highly damaging le-
sions, can block replication and are both cytotoxic 
and mutagenic (Loeb & Preston, 1986; Guillet & Boi-
teux, 2003). Additionally, unrepaired AP-sites may 
rearrange to generate SSBs (Lindahl, 1993).
Alkylation of DNA bases
Alkylating agents can react with 12 differ-
ent positions of DNA bases, including all exocyclic 
oxygens and most of ring nitrogens, and can also 
modify oxygen atoms in the phosphates groups of 
the sugar-phosphate backbone. Depending on the 
mode of action, alkylating agents are divided into 
two types: SN1-type agents (e.g. N-methyl-N-nitro-
sourea, MNU) alkylate both oxygens and nitrogens 
in nucleic acids, and SN2-type agents (e.g. methyl 
methanesulfonate, MMS) alkylate mainly nitrogens. 
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In general, ring nitrogen atoms engaged in hydrogen 
bonding are almost non-reactive in double-stranded 
DNA (dsDNA), but can be more readily alkylated in 
single stranded DNA (ssDNA) or RNA (e.g. N3 of 
cytosine and N1 of adenine) (reviewed by: Drablos et 
al., 2004; Sedgwick, 2004; Nieminuszczy & Grzesiuk, 
this issue). The major product of DNA base meth-
ylation is N7-methylguanine, a rather non-muta-
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Figure 1. Major endogenous DNA base modifications.
Modified positions are shown in red.
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genic and non replication-blocking lesion. However, 
destabilization of the N-glycosidic bond due to the 
N7-substitution of guanine results in the formation 
of AP-sites or imidazole ring opening to yield very 
mutagenic lesion 7me-FapyG (Tudek et al., 1992). 
The second most common DNA base methylation is 
N3-methyladenine (3-meA), which is a potent repli-
cation-blocking lesion and is perhaps the most toxic 
adduct produced by alkylating agents, resulting in 
TP53 induction, S-phase arrest, chromosomal aberra-
tions and apoptosis (Engelward et al., 1998). In con-
trast to the limited miscoding potential of N-purines, 
O6-methylguanine (O6-meG) and, to a lesser extent, 
O4-methylthymine (O4-meT) are major contribu-
tors to mutagenicity induced by alkylating agents. 
Endogenous agents may alkylate DNA bases, and 
among them the best known is S-adenosyl-l-methio-
nine (SAM) (Rydberg & Lindahl, 1982). Physiologi-
cally, SAM is a methyl donor in many biochemical 
reactions, and among others it participates in enzy-
matic methylation of DNA cytosines at C5 position, 
which, in Eukaryotes, regulates gene expression. 
Furthermore, adenine methylation in the GATC se-
quences is used by the MMR system to distinguish 
between the newly synthesized and template DNA 
strands in E. coli cells (reviewed by Arczewska & 
Kusmierek, this issue).
Oxidation-induced DNA damage
Reactive oxygen species (ROS), together with 
reactive nitrogen species (RNS) are known to induce 
both deleterious and beneficial effects. They can 
be induced by exogenous or environmental factors 
such as UV light, X-rays or γ-rays (which produce 
hydroxyl radical (•OH) by radiolysis of water), xe-
nobiotics, cigarette smoke are present as pollutants 
in the atmosphere. Endogenously, they are formed 
as by-products of the respiratory electron transport 
chain, cytochrome P450 and xanthine oxidase me-
tabolism, by micorsomes and peroxisomes, and are 
also produced by neutrophils, eosinophils and mac-
rophages during inflammation and in various metal-
catalyzed reactions (reviewed by: Valko et al., 2006). 
Aerobically growing cells depend on energy formed 
by reduction of atmospheric oxygen (O2) to H2O by 
the respiratory electron transport chain (Babcock & 
Wikstrom, 1992). The main product of mitochondrial 
respiration is superoxide anion radical (O2•−), which 
shows limited reactivity, but upon escape from the 
respiratory electron transport chain induces side 
effects by further conversion to H2O2 by superox-
ide dismutase (SOD), and then to hydroxyl radical 
(•OH). O2•− induces •OH formation in the Haber-
Weiss reaction (O2•− + H2O2 → O2 + •OH + OH−) 
and also liberates Fe3+ from ferritin and reduces it to 
a Fenton reaction constituent, Fe2+, or liberates Fe2+ 
from iron-sulfur cluster-containing enzymes (Krusze-
wski & Iwanenko, 2003). H2O2 can be reduced to 
water by catalase and glutathione peroxidase. How-
ever, in the presence of transition metal ions, such 
as iron or copper, H2O2 is reduced to •OH by the 
Fenton-type reaction (H2O2 + Fe2+ → •OH + OH− + 
Fe3+). The reactivity of •OH is so high that it can dif-
fuse no further than one or two molecular diameters 
before reacting with a cellular component, so it must 
be generated close to the DNA molecule to be able 
to oxidize it (Michiels et al., 1994).
In terms of the potential to generate modi-
fied bases, oxidation represents the major contribu-
tor to baseline DNA damage, with estimates of the 
total number of oxidized bases formed approxi-
mating 10 000 adducts per cell per day. Nearly one 
hundred different free radical DNA modifications 
have been identified, classified as base- or deoxy-
ribose lesions, strand breaks and cross-links, and 
among them base alterations comprise about 50 le-
sions (Halliwell & Aruoma, 1991; Dizdaroglu, 1992). 
Free radicals attack thymine at two principal sites, 
i.e. the 5,6-double bond and 5-methyl group. The 
following oxidized thymines have been detected 
in DNA: thymine glycol (Tg), 5,6-dihydrothymine 
(diHT), 5-hydroxy-5,6-dihydrothymine (5-OH-diHT) 
and 6-hydroxy-5,6-dihydrothymine (6-OH-diHT), 
5-hydroxy-5-methylhydantoin (hmh), and many 
others. Cytosine is oxidized only at the 5,6-double 
bond, which results in changing the planar aromatic 
ring structure into a non-planar non-aromatic struc-
ture, similarly as in the case of thymine. The main 
oxidative cytosine modifications found in DNA are 
5,6-dihydroxy-5,6-dihydrocytosine (cytosine glycol, 
Cg), its deamination and dehydration products 5,6-
dihydroxy-5,6-dihydrouracil (uracil glycol, Ug) and 
5-hydroxycytosine (5-OH-C), respectively; 5-hydroxy-
uracil (5-OH-U) (formed from Ug by dehydratation 
or from 5-OH-C by deamination), and many others 
(Kreutzer & Essigmann, 1998; Purmal et al., 1998).
Hydroxyl radicals react with C8 of guanine, 
yielding C8-OH adduct radical. The C8-OH adduct 
radical is oxidized to 7,8-dihydro-8-oxodeoxyguanine 
(8-oxoG) or is reduced to 2,6-diamino-4-hydroxy-5-
formamidopirymidine (FapyG). Both 8-oxoG and 
FapyG are the major oxidative damages of guanine, 
and 8-oxoG is regarded as the most abundant oxida-
tive DNA damage being often used as the marker 
of cellular oxidative stress. Two or three residues of 
8-oxoG are present per 106 G sites in human leuko-
cytes and roughly 80 8-oxoG residues are continu-
ously generated per human cell per day (Lindahl, 
1993; Halliwell, 1999).
Hydroxyl radicals and peroxynitrite can cause 
damage to DNA both by direct attack on the bases 
or sugar moieties or indirect, via cell membranes li-
pids peroxidation (LPO). LPO products interact with 
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DNA resulting in generation of adducts to bases, 
abasic sites, single or double strand breaks and sub-
sequently chromosomal alterations. Polyunsaturated 
fatty acids (PUFAs) are constituents of phospholipid 
membranes, with the most abundant linoleic and 
arachidonic acids. Attack of ROS and RNS on poly-
unsaturated fatty acids causes formation of radicals 
and breaking of double bonds, which leads to lipid 
molecules fragmentation with generation of alde-
hydes, epoxides and other reactive keto-compounds, 
such as malondialdehyde, acrolein, crotonaldehyde, 
trans-4-hydroxy-2-nonenal, and 2,3-epoxy-4-hydoxy-
nonenal. These lipid peroxidation compounds react 
with exocyclic nitrogen atoms of DNA bases and 
form exocyclic DNA adducts, in this indirect path-
way contributing to oxidative DNA damage (Bur-
cham, 1998).
DNA damage induced by other exogenous  
and endogenous factors
Apart from the above-described agents also 
numerous other endogenous and exogenous factors 
contribute to DNA damage and human diseases. 
These endogenous factors which can induce DNA 
modification include: (i) base propenols, formed by 
oxidative DNA damage; (ii) estrogens, which can in-
duce DNA damage directly and indirectly, through 
redox-cycling processes that generate reactive radi-
cal species; (iii) reactive carbonyl species (RCS) (e.g. 
glyoxal and methylglyoxal), originating from lipid 
peroxidation and glycation; (iv) chlorinating agents; 
(v) heme precursors; (vi) and also amino acids (re-
viewed by: Burcham, 1999). Another important envi-
ronmental source of DNA damage is UV light, which 
induces formation mainly of cyclobutane pyrimidine 
dimers (CPDs) and 6–4 photoproducts ([6–4]PPs), 
which have proved to be involved in skin carcino-
genesis (reviewed by: Pfeifer et al., 2005).
DNA damage induced by anti-cancer treatments
Agents that induce DNA damage in cells and 
inhibit DNA repair have successfully been used for 
decades to treat patients with tumors (Bentle et al., 
2006). The DNA affected by anti-cancer treatments 
is detected by DNA damage sensors, which leads to 
the activation of TP53. Activation of TP53 can lead 
to the death of cancer cells (Roos & Kaina, 2006). 
The efficacy of genotoxins used in humans as an-
ticancer agents is, however, limited by their toxic-
ity to normal tissues. Specific sensitization of tumor 
cells to the action of anti-cancer treatments would 
reduce the efficacious doses of genotoxins to be 
used in patients, diminishing the detrimental side-
effects of the drugs on normal tissues. Some drugs, 
namely bleomycin and neocarzinostatin act by in-
duction of DNA strand breaks (Dedon & Goldberg, 
1992; Dedon et al., 1992). DNA cleavage by bleomy-
cin depends on oxygen and metal ions. It is believed 
that bleomycin chelates metal ions (primarily iron) 
producing a pseudoenzyme that reacts with oxygen 
to produce superoxide and hydroxide free radicals 
that cleave DNA. In addition, these complexes also 
mediate lipid peroxidation and oxidation of other 
cellular molecules. The drug is used in the treatment 
of Hodgkin lymphoma, squamous cell carcinomas, 
and testicular cancer, pleurodesis as well as plantar 
warts (Katsara et al., 2006; Kopp et al., 2006; Proctor 
& Wilkinson, 2006). Temozolomide is an alkylating 
agent which forms O6-meG, 7-meG, 3-meA base le-
sions in DNA. The drug is used for the treatment of 
refractory anaplastic astrocytoma, a type of cancer-
ous brain tumor (Rabbani et al., 2007).
BER AS tHE MOSt fREquENtLy uSED DNA 
REPAIR
The base excision repair pathway is responsi-
ble for removal of more than 10 000 DNA lesions dai-
ly in each human cell. In addition, lesions targeted 
by the BER pathway are relatively small, causing lit-
tle helix distortion. Many of these lesions have been 
shown not to inhibit elongation by some DNA and 
RNA polymerases both in vivo and in vitro (Doetsch, 
2002). However, BER is the major repair pathway 
involved in the removal of DNA damage involving 
structurally non-distorting and non-bulky lesions, 
e.g. oxidized or ring-saturated bases, alkylated and 
deaminated bases, as well as apurinic/apyrimidinic 
sites, and also some type of mismatches (Lindahl et 
al., 1997). Proteins engaged in BER are conserved 
from bacteria to eukaryotes. BER is initiated (i) by a 
damage-specific DNA N-glycosylase that recognizes 
and removes the modified or mismatched base by 
hydrolysis of the N-glycosidic bond between a 2’-de-
oxyribose and the base, or (ii) by non-enzymatic hy-
drolytic depurination leading to base loss (described 
above), as well as (iii) by SSBs with ends other than 
3’-OH and 5’-P.
DNA damage recognition by DNA N-glycosylases
At least 12 genes (plus their splicing vari-
ants) and eight ones encoding various glycosylases 
have been found in mammalian and Escherichia coli 
cells, respectively, with different substrate specifici-
ties and modes of action (summarized in Table 1). 
Glycosylases effectively ensure repair of the major-
ity of endo- and exogenous DNA base lesions. They 
often contain a conserved motif of helix-harpin-helix 
(HhH) in the active site, which enables them to bind 
DNA. These HhH motifs bind a metal ion but only 
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during contact with DNA. Four structural super-
families of DNA glycosylases have been identified. 
UDG superfamily-1 is based on structural similarity 
to uracil DNA glycosylase UDG. Enzymes belong-
ing to this family are active against uracil in ssDNA 
and dsDNA, and recognize uracil explicitly in an 
extrahelical conformation via a combination of pro-
tein and bound-water interactions. Some of these en-
zymes are mismatch specific and explicitly recognize 
the widowed guanine on the complementary strand 
rather than the extrahelical scissile pyrimidine. AAG 
superfamily-2 is based on structural similarity to hu-
man alkyladenine DNA glycosylase AAG. Members 
of the UDG and AAG superfamilies are compact sin-
gle-domain enzymes with relatively small DNA-in-
teraction surface. MutM/Fpg superfamily-3 is based 
on structural similarity to bacterial 8-oxoguanine 
DNA glycosylase Fpg. All known members have the 
unique feature of using their N-terminal proline res-
idue as the key catalytic nucleophile. HhH-GPG su-
perfamily-4 is named for the characteristic active site 
borne by family members comprising a helix-harpin-
helix followed by a Gly/Pro-rich loop and catalytic 
aspartate residue (reviewed by: Pearl, 2000; Fromme 
et al., 2004).
Glycosylases are generally divided into two 
types: (i) E. coli Tag, AlkA, UDG, Mug, and MutY 
and human ANPG, hUNG1 and hUNG2, hSMUG1, 
hTDG, hUDG2, MUTYH, and hMBD4 monofunc-
tional DNA N-glycosylases that remove a deami-
nated, alkylated or mismatched base leaving an AP-
site, and (ii) E. coli Fpg, Nth, and Nei and human 
hOGG1, hOOG2, hNTH1, hNEIL1, hNEIL2, and 
hNEIL3 bifunctional DNA N-glycosylases/AP-lyases 
that remove oxidized or ring-saturated bases and 
additionally to the glycosylase activity have a 3’-AP-
lyase activity which incises the phosphodiester bond 
at the 3’ side of the deoxyribose via β-elimination 
leaving a single strand break (SSB) with 3'-phospho-
α,β-unsaturated aldehyde (3'-PUA) and 5'-phosphate 
(5'-P) ends. Moreover, E. coli Fpg and Nei or mam-
malian NEIL1 and NEIL2 bifunctional glycosylases 
additionally carry out δ-elimination reaction with re-
moval of the deoxyribose residue and generation of 
3'-phosphate termini (3'-P).
Role of end-processors in DNA repair
The AP-sites or DNA ends generated after le-
sion excision or excision and incision by mono- or 
bifunctional glycosylases, respectively, are not suit-
able for the next repair steps, and as the repair in-
termediates are very mutagenic when unrepaired by 
BER (Simonelli et al., 2005). DNA ends containing 
modified 3’ and/or 5’ ends may also arise as a result 
of direct chemical modification during SSB forma-
tion through the action of ROS (Demple & DeMott, 
2002). However, ionizing radiation is a major con-
tributor to the formation of damaged 3’ ends, and 
anti-tumor drugs, such as bleomycin and neocarzi-
nostatin, can also generate SSBs containing 3’ PUA 
and 3’-P, respectively (Dedon & Goldberg, 1992). 
Moreover, blocked 3’ ends in human cells may arise 
as a result of abortive DNA topoisomerase I (TOP1) 
activity (reviewed in (Leppard & Champoux, 2005).
At least a few enzymes occur in E. coli and 
human cells that can restore conventional 3’-OH and 
5’-P moieties to allow gap filling and DNA ligation 
(summarized in Table 2). DNA-end processing is 
probably the most diverse enzymatic step due to the 
variety of termini that can arise.
AP-endonuclease (APE) is the main enzyme 
responsible for processing of the BER-intermediates. 
APE generates 3’-OH termini either by cleaving the 
phosphodiester bond at the 5’ side of the intact AP-
site (after action of a monofunctional N-glycosylase 
or hydrolytic depurination) by its 5’-AP-lyase activ-
ity, leaving 5’-deoxyribose phosphate (5’-dRp), or by 
removal of 3’-PUA or 3’-P (after double action of a 
bifunctional N-glycosylase) by its 3’-phosphoesterase 
and 3’-phosphatase activities, respectively. E. coli 
APEs, Xth (exonuclease III) and Nfo (endonucle-
ase IV) efficiently incise AP sites and remove both 
β- and β/δ-elimination products, but mammalian 
APE1 (termed also APEX, HAP1 or Ref-1) and APE2 
have strong AP-lyase and 3'-phosphoesterase activi-
ties (Burkovics et al., 2006), respectively, but their 3’-
phosphatase activities appear to be very weak. Ad-
ditionally, Xth, APE1 and APE2 also possess a 3’→
5’ exonuclease activity that allows them to remove 
more than one nucleotide. Xth, APE1 and APE2 can 
act as a proofreading activity in BER (Hadi et al., 
2002; Burkovics et al., 2006).
Additionally, 3’-P can be removed by mam-
malian polynucleotide kinase (PNK), which, togeth-
er with NEIL1/NEIL2 glycosylases, forms the APE-
independent BER subpathway (Wiederhold et al., 
2004). Human PNK is the major DNA 5’-kinase and 
3’-phosphatase that is able to phosphorylate the 5’ 
end of SSBs and removes blocking phosphate lesions 
from the 3’ end (reviewed by: Dianov & Parsons, 
2007). Moreover, also E. coli nucleoside diphosphate 
kinase (NDK) has been shown to have AP-lyase, 3’-
phosphodiesterase, 3’-phosphatase and 3’→5’ exonu-
clease activities (Postel & Abramczyk, 2003; Goswa-
mi et al., 2006) but its role in BER is still unclear. An 
E. coli strain lacking NDK shows elevated levels of 
MMR-dependent base substitutions and frameshifts, 
induced probably by an altered dNTP pool. All 
these NDK activities provide a good explanation of 
the mutator phenotypes induced by NDK depletion 
(Postel & Abramczyk, 2003; Goswami et al., 2006). 
Furthermore, human NM23/NDP kinase has been 
identified as tumor suppressor, and is associated 
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with tumor metastasis. Its reduced expression seems 
to be related to an increased metastatic potential in 
most cancer cell types. Moreover, NM23/NDK kinase 
was also shown to activate transcription and to have 
a nuclease activity (Postel et al., 2000; 2002).
Although, tyrosyl-DNA phosphodiesterase 
1 (TDP1) is not involved in the major BER path-
way, it may be a DNA-end processor during SSBs 
repair. The primary substrates for TDP1 are the 
TOP1-linked 3’ ends (TOP1-SSBs) that arise through 
abortive topoisomerase I (TOP1) activity, which can 
be induced by the drug camptothecin or by nearby 
unusual DNA secondary structures or other types 
of DNA lesions (Plo et al., 2003; Caldecott, 2007; El-
Khamisy et al., 2007). TDP1 converts the 3’-TOP1-
SSB peptide complex into a 3’-P end further proc-
essed by PNK (Connelly & Leach, 2004). TDP1 is 
mutated in the neurodegenerative disease spinocer-
ebellar ataxia with axonal neuropathy-1 (SCAN1). In 
addition to being defective in the removal of stalled 
3’-TOP1–SSB intermediates, SCAN1 cells also exhibit 
a reduced capacity to excise the 3’-phosphoglycolate 
end, a common oxidative damage (Straussberg et al., 
2005; Zhou et al., 2005).
Aprataxin (APTX), the protein defective in 
the neurological disorder ataxia oculomotor aprax-
ia (AOA1), is a member of the HIT domain super-
family of nucleotide hydrolases/transferases. Cells 
deficient in APTX are defective in SSBR. APTX has 
been found to be involved in resolution of abortive 
DNA ligation intermediates by catalysing the nucle-
ophilic release of adenylate groups covalently linked 
to 5’P-ends at single-strand nicks and gaps (Ahel et 
al., 2006). APTX is also responsible for the repair of 
typically endogenous damage produced by reactive 
oxygen species on 3’ DNA ends, including 3’-PUA 
and 3’-P (Takahashi et al., 2007). APTX acts prefer-
entially on adenylated nicks and DSBs rather than 
on SSBs. Moreover, APTX has been found  to act in 
BER, specifically in the removal of adenylates that 
arise from abortive ligation reactions that take place 
at incised AP-sites in DNA, and may have a gen-
eral proofreading function in DNA repair, removing 
DNA adenylates as they arise during SSBR, DSBR, 
and in BER (Rass et al., 2007).
Flap endonuclease activity (FEN-1) possesses 
(i) 5’→3’ exonuclease activity which is involved in 
maturation of Okazaki fragments during mamma-
lian DNA replication, and (ii) endonuclease activ-
ity which removes 5’-dRP-containing flap during 
LP-BER (Garg & Burgers, 2005; Liu et al., 2005). 
Fen1–/– knockout mice are not viable (Friedberg & 
Meira, 2004).
Recently, it has been found that the high-mo-
bility group box 1 protein (HMGB1) specifically in-
teracts with a BER intermediate. HMGB1 possesses 
weak dRP-lyase activity and stimulates AP-endonu-
clease and FEN1 activities on BER substrates (Prasad 
et al., 2007).
DIffERENt BER SuB-PAtHwAyS
BER proceeds further via two alternative sub-
pathways (Fig. 2): short-patch (SP), which involves 
replacement of one nucleotide, or long-patch (LP), 
which involves replacement of several nucleotides 
(at least 2, often 6–13 nucleotides).
SP-BER
Oxidized and ring-saturated bases are recog-
nized and removed from DNA by the bifunctional 
DNA N-glycosylases/AP-lyases. Next, APEs remove 
3’-PUA and 3’-P (for more details see above) leav-
ing 3’-OH and 5’-P ends suitable for filling by mam-
malian Pol β or E. coli Pol I and for end-sealing by 
mammalian LIG3α or bacterial ligase I. In contrast, 
alkylated and deaminated bases as well as some 
types of mismatches, are recognized and removed 
from DNA by the monofunctional DNA N-glycosy-
lases. In this process the N-glycosydic bond connect-
ing the aberrant base to the sugar-phosphate back-
bone is cleaved and an AP-site is created (Krokan et 
al., 1997). The AP-site is recognized and processed 
by the APEs (Taylor & Weiss, 1982) that hydrolyze 
the phosphodiester DNA backbone at the 5’ side of 
the AP-site, leaving 3’-OH and 5’-dRP ends flanking 
the gap. From this point, the choice of the pathway 
depends on the ability of the enzymes to remove 
the 5’-sugar phosphate. In mammalian cells both 
pathways are initiated by Pol β, which inserts one 
nucleotide into the repair gap. In SP-BER Pol β also 
removes 5'-dRP by its 5'-dRPase activity, and finally 
DNA LIG3α–XRCC1 complex seals the ends. Addi-
tionally, Pol λ may partially backup Pol β, since it 
has a 5'-dRPase activity. XRCC1 is a platform protein 
and was shown to interact with Pol β, LIG3α, PNK, 
APE1 and PARP-1 (Fig. 3). The lesions removed by 
bifunctional DNA glycosylases are processed mainly 
by SP-BER, since the 3'-OH and 5'-phosphate ends 
may be readily filled in by Pol β. In E. coli, 5’-dRP is 
removed by Fpg, Nei, or RecJ or by the 5’→3’ exo-
nuclease activity of Pol I, and the resulting gap is 
filled in by Pol I and sealed by DNA ligase I.
LP-BER
In human cells modification of the 5’-dRP 
moiety by oxidation or reduction prevents its exci-
sion by Pol β and the lesion is further processed by 
LP-BER. First, Pol β falls off and PCNA (replica-
tion sliding clamp) is recruited together with Pol δ 
or Pol ε. The polymerase adds a few nucleotides to 
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figure 2. Model for the BER and SSBR subpathways.
P, phosphate; OH, hydroxyl group; 3’PUA, 3’-unsaturated aldehyde; 5’dRp, 5’-deoxyribose phosphate; AMP, adenylate 
group; TOP1, topoisomerase I-linked 3’-end.
The types of DNA lesions repaired by common subpathways of single strand breaks repair and base excision repair 
are marked in purpure. Escherichia coli enzymes are on left, and are in blue, human enzymes shown on right, are in 
red.
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the 3'-OH end and generates a flap containing the 
5'-dRP end, which is then removed by FEN-1 and 
finally the ends are sealed by DNA ligase I (LIG1). 
PCNA interacts not only with the polymerase, but 
also with FEN-1 and LIG1 (Fig. 3). Furthermore, 
replication protein A (RPA), which interacts with 
the MUTYH and UNG2 glycosylases, is required by 
Pol δ and Pol ε for DNA synthesis, and may stimu-
late LP-BER. Pol δ requires also replication factor 
C (RF-C; which loads the PCNA sliding clamp on 
the double helix) and PCNA for efficient synthesis, 
while Pol ε is highly processive in the absence of 
PCNA (reviewed by: Krokan et al., 1997; Nilsen & 
Krokan, 2001; Dianov et al., 2003; Slupphaug et al., 
2003; Sung & Demple, 2006). If in E. coli cells the 5’-
dRp residue is not removed prior to repair synthesis, 
Pol I displaces the dRP-containing strand via a strand 
displacement reaction (Mosbaugh & Linn, 1982) dur-
ing filling of the gap. The displaced strand is cleaved 
by the 5’→3’ exonuclease activity of Pol I (Xu et al., 
1997; Xu et al., 2001), and 2 to 8 or even more nucle-
otides are removed and replaced, leading to so-called 
long-patch BER (LP-BER) (Radicella et al., 1993; Sung 
& Mosbaugh, 2003). Furthermore, the length of repair 
synthesis may also be determined by the availabil-
ity of DNA ligase I, its lack leading to longer repair 
patches in vitro (Sung & Mosbaugh, 2003).
In mammalian cells 8-oxoG is repaired via a 
2–6-nucleotide patch, since the hOGG1 3’-AP-lyase 
activity is 10 times lower than its N-glycosylase 
activity, and repair proceeds via LP-BER (Sattler et 
al., 2003). Furthermore, APE1 has been shown to 
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figure 3. Scheme of interaction between the main proteins involved in human BER and SSBR.
Cartoon is based on: for APE1 interaction: (Bennett et al., 1997; Privezentzev et al., 2001; Vidal et al., 2001b; Yang et al., 
2001; Kavli et al., 2002; Marenstein et al., 2003; Xia et al., 2005), for XRCC1 interaction: (Caldecott et al., 1995; Vidal et al., 
2001a; Whitehouse et al., 2001; Plo et al., 2003; Clements et al., 2004; Dianova et al., 2004; Caldecott, 2007), for PARP in-
teraction: (Allinson et al., 2003; Leppard et al., 2003; von Kobbe et al., 2003; von Kobbe et al., 2004; Thorslund et al., 2005), 
for PCNA interaction: (Klungland & Lindahl, 1997; Parker et al., 2001; Xia et al., 2005; Fortini & Dogliotti, 2007; Wilson & 
Bohr, 2007).
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increase hOGG1 turnover on damaged DNA and 
stimulate its excision activity (Hill et al., 2001). BER 
is further complicated by other proteins which in-
teract with its components (Fig. 3). PARP-1 binds to 
SSB immediately after its formation and dissociates 
after self-poly(ADP-ribosyl)ation. PARP-1 has been 
proposed to prevent cleavage of the strand break 
ends by nucleases, and was also shown to stimulate 
LP-BER strand displacement synthesis by Pol β (Di-
anov et al., 2003; Parsons et al., 2005). Furthermore, 
Werner syndrome protein (WRN) stimulates Pol β 
strand displacement DNA synthesis via its helicase 
activity, and provides proofreading of 3’-mismatches 
via its 3’→5’ exonuclease activity (which is absent in 
Pol β) (Harrigan et al., 2006). Additionally, Cockayne 
syndrome group B (CSB) functions in the catalysis 
of 8-oxoG excision by BER and in the maintenance 
of efficient hOGG1 expression (Tuo et al., 2002).
MutAgENESIS IN E. coli cELLS cAuSED By 
DySfuNctION Of BER PROtEINS
DNA guanine is frequently oxidized to 
8-oxoG, which, if unrepaired, can be bypassed by 
DNA polymerases and pair with its cognate C as 
well as noncognate A, leading to GC→TA transver-
sions. E. coli has evolved a complicated strategy to 
avoid mutations from this commonly oxidized base. 
Fpg (also called MutM), removes 8-oxoG paired with 
C in DNA, while the MutY protein removes A mi-
spaired with 8-oxoG. Finally, the MutT protein, an 
8-oxodGTPase, removes oxidized dGTPs from the 
nucleotide pool, preventing their misincorporation 
opposite adenine (reviewed by Arczewska & Kus-
mierek, this issue). E. coli mutants defective in Fpg 
or MutY, and double mutants lacking both proteins, 
exhibit higher than wild type spontaneous mutation 
frequencies (Au et al., 1988; Cabrera et al., 1988; Boi-
teux & Huisman, 1989; Michaels et al., 1991; Fowler 
et al., 2003; Speina et al., 2005b; Hamm et al., 2007). 
Mutants lacking the MutT protein also exhibit high 
spontaneous mutation frequencies (Akiyama et al., 
1989). Oxidized pyrimidines are repaired in E. coli by 
Nth (endo III) and Nei (endo VIII). The nth mutants 
exhibit a small mutator phenotype, while nei mutants 
exhibit no mutator phenotype. Double mutants, lack-
ing both proteins, exhibit spontaneous mutation fre-
quency higher than the wild type (Saito et al., 1997). 
Surprisingly, triple mutants lacking Fpg, MutY, and 
Nei and quadruple mutants lacking all four DNA 
glycosylases, Fpg, MutY, Nei, and Nth, exhibit sig-
nificant synergistic effects, suggesting an overlap in 
the substrate specificities of the “pyrimidine-spe-
cific” and “purine-specific” enzymes (Blaisdell et 
al., 1999). Moreover, the nth nei double mutants are 
hypersensitive to ionizing radiation and hydrogen 
peroxide but not as sensitive as APEs mutants xth 
nfo. Single nth mutants exhibit wild-type sensitivity 
to X rays, while nei mutants are consistently slightly 
more sensitive than the wild type. Additionally, ung 
cells are not able to initiate base excision repair of 
uracil-containing DNA. These mutants have a high 
GC→AT mutation rate because they are not able to 
repair deaminated cytosine residues. Uracil residues 
also accumulate in the DNA of ung mutants as a 
consequence of the occasional biosynthetic incorpo-
ration of uracil into DNA in place of thymine (Dun-
can & Weiss, 1982). The mug mutant does not show 
a mutator phenotype in dividing E. coli, and is only 
a modest mutator in stationary phase cells (Jurado 
et al., 2004). It is possible that this lack of a strong 
phenotype is caused by the presence of alternative 
enzymes in E. coli that process the promutagenic le-
sion U and the T : G mispair. However, E. coli mug 
mutant is sensitive for agents causing etheno-ad-
ducts (Maciejewska, unpublished; Borys-Brzywczy 
et al., 2005). Moreover, E. coli possesses two differ-
ent DNA repair glycosylases, Tag and AlkA, which 
have similar ability to remove the alkylation prod-
uct 3-meA from dsDNA. These enzymes have quite 
different activities for the excision of 3-meA from 
ssDNA, AlkA being 10–20 times more efficient than 
Tag. AlkA may have an important role in the exci-
sion of base damage from single-stranded regions 
transiently formed in DNA during transcription and 
replication (Bjelland & Seeberg, 1996). All bacterial 
DNA N-glycosylases are summarized in Table 1. The 
double xth nfo E. coli strain devoid of BER is very 
sensitive to H2O2 and MMS. Moreover, the triple 
mutant for the DNA repair genes xth nth nfo, chroni-
cally induces the SOS response (Janion et al., 2003). 
Bacterial nucleases are summarized in Table 2.
PROcESSES cONtROLLED By DNA 
gLycOSyLASES IN HuMAN cELLS
The sources of uracil in DNA are spontaneous 
or enzymatic deamination of cytosine (U:G mispairs) 
and incorporation of dUTP (U : A pairs), inducing 
CG→TA transitions during DNA replication (Dun-
can & Weiss, 1982). Uracil is usually an inappropri-
ate base in DNA, but it is also a normal intermedi-
ate during somatic hypermutation (SHM) and class 
switch recombination (CSR) in adaptive immunity. 
In B-cells cytosine is actively deaminated to uracil 
by activation-induced cytosine deaminase (AID), 
which leads to numerous CG→TA transitions in the 
immunoglobulin (Ig) Ig locus. This process increases 
immunoglobulin diversity. Paradoxically, proteins 
involved normally in error-free base excision repair 
and mismatch repair, seem to be co-opted to facili-
tate SHM and CSR, by recruiting error-prone transle-
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sion polymerases to the DNA temple containing dU 
created by AID (Neuberger et al., 2003; Samaranay-
ake et al., 2006).
Mammalian cells posses at least four enzymes 
with UDG activity, namely UNG, TDG, SMUG1 and 
MBD4. The major ones are nuclear UNG2 and mito-
chondrial UNG1 encoded by the UNG gene (Nilsen 
et al., 1997) and SMUG1 that also removes oxidized 
pyrimidines. The other ones are TDG that removes 
U and T from mismatches arising after deamination 
of C and 5-meC, respectively, and methyl binding 
domain IV (MBD4) that removes U from CpG con-
texts. UNG2 is found in replication foci during the 
S-phase and has a distinct role in the repair of U : A 
pairs, but it is also important in U : G repair, a func-
tion shared with SMUG1. Humans lacking UNG2 
suffer from recurrent infections and lymphoid hy-
perplasia, and have skewed SHM and defective 
CSR, resulting in elevated IgM and strongly reduced 
IgG, IgA and IgE. UNG-defective mice also develop 
B-cell lymphoma late in life. The Phe251Ser UNG2 
variant protein has been found to be mistargeted to 
mitochondria, resulting in deficient nuclear activity 
and increased uracil genomic content (Akbari et al., 
2007; Kavli et al., 2007).
5-meC is normally present in DNA and con-
stitutes up to 30% of total number of cytosines in 
the mammalian cell and at CpG sequences 5-meC 
is involved in silencing of gene expression (Li et al., 
1992; Yoder et al., 1997). In humans, G : T mispairs 
arise from replication errors, which are handled by 
the mismatch repair pathway, or from the deami-
nation of 5-meC to T. Because cytosine methylation 
occurs at CpG dinucleotides, G : T mispairs caused 
by  5-meC deamination are found at CpG sites. It 
has been shown that TDG is active for G : T mispairs 
with a 5’ C : G pair, suggesting that a predominant 
biological role of the enzyme is to initiate the repair 
of CpG : T lesions. However, the U : G mispair is the 
most efficiently processed physiological substrate 
for TDG (Gallinari & Jiricny, 1996; Hardeland et 
al., 2001; Cortazar et al., 2007). Epigenetic silencing 
through methyl-CpG (mCpG) is implicated in many 
biological patterns such as genomic imprinting, X 
chromosome inactivation, and cancer development 
as well as the silencing of repetitive genetic ele-
ments. According to the facts described above, TDG 
could contribute to tumor suppression in a number 
of different ways: it may (i) help maintain genomic 
stability through the repair of mutagenic DNA base 
damage (e.g. deamination of C or 5-meC); (ii) pro-
vide epigenetic stability through the excision of erro-
neously methylated Cs in gene regulatory sequences; 
(iii) and/or it may assure proper cell differentiation 
and control the number of stem cells and/or tumor 
progenitor cells in certain tissues by its ability to 
cooperate with nuclear receptors and other tran-
scription factors that integrate differentiation signals 
(Cortazar et al., 2007).
Another human DNA glycosylase, mentioned 
earlier, MBD4, exhibits specificity for G : T mispairs 
at CpG sites and also plays a role in the integrity of 
CpG sites (Hendrich et al., 1999). It has been shown 
that MBD4 binds to hypermethylated promoter of 
the MLH1 gene (MLH1 is a MMR protein). These re-
sults suggest that also MBD4 is one of the essential 
components involved in epigenetic silencing and its 
repair activity is necessary for the maintenance of 
hypermethylated promoters (Kondo et al., 2005).
Taking it all together, in human cells a few 
mechanisms exist that regulate the level and activ-
ity of DNA glycosylases by post-translational modi-
fications (reviewed by: Tudek, 2007). Also UNG2 
expression is up-regulated during S-phase of the 
cell cycle where the protein associates with PCNA 
and RPA at replication foci, implicating a role for 
this glycosylase in the removal of misincorporated 
U during DNA replication. Conjugation of SUMO 
to TDG induces glycosylase dissociation from DNA 
(Baba et al., 2006). Cells entering S-phase eliminate 
TDG through the ubiquitin-proteasome pathway. 
Degradation of TDG is critical for S-phase progres-
sion and cell proliferation. Strikingly, TDG levels de-
cline just when UNG2 expression goes up and vice 
versa, suggesting that uracil repair is handled by dis-
tinct pathways throughout the cell cycle that are co-
ordinated by the ubiquitin-proteasome system. The 
inability of TDG to discriminate between the paren-
tal and newly synthesized DNA strands would fix 
C→T transition mutations in cases where the T is in 
the parental strand. In addition, TDG-induced pos-
treplicative G : T repair in the parental DNA strand, 
particularly in the parental lagging strand, could 
destabilize the replication fork and thereby impede 
the replication process. Thus, G : T correction during 
DNA synthesis should be left to the postreplicative 
mismatch repair system, which is designed to cor-
rect the error in the newly synthesized DNA strand 
(Hardeland et al., 2007).
Expansion of CAG trinucleotide repeats en-
coding polyglutamine has been identified as the 
pathogenic mutation in at least nine different genes 
associated with hereditary neurodegenerative disor-
ders, including Huntington’s disease (HD), denta-
torubral pallidoluysian atrophy (DRPLA), spinal and 
bulbar muscular atrophy (SBMA), and the spinocer-
ebellar ataxias: SCA1, SCA2, SCA3 (also known as 
Machado-Joseph disease), SCA6, SCA7, and SCA17 
(Adachi et al., 2007; Underwood & Rubinsztein, 2007; 
Walker, 2007). Also, the two most common triplet ex-
pansion human diseases, myotonic dystrophy 1 and 
fragile X syndrome, are caused by expanded CTG/
CAG and CGG/CCG repeats, respectively (Wang, 
2007). Moreover, oxidative lesions are known to be 
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associated with ageing and neurological diseases 
(Olinski et al., 2007). Recently it has been found 
that the age-dependent somatic mutation associated 
with Huntington’s disease occurs in the process of 
removing oxidized base lesions (8-oxoG) and is re-
markably dependent on OGG1. OGG1 was shown 
to initiate an escalating oxidation-excision cycle that 
leads to progressive CAG expansion. Age-depend-
ent CAG expansion provides a direct molecular link 
between oxidative damage and toxicity in post-mi-
totic neurons through a DNA damage response and 
error-prone repair of SSBs (Kovtun et al., 2007).
cOuLD APc BE A fActOR DEtERMININg tHE 
PAtcH SIzE DuRINg REPAIR SyNtHESIS?
The adenomatosis polyposis coli (APC) tumor 
suppressor is a multifunctional protein that is mu-
tated in a majority of colon cancers. Close exami-
nation of the function of APC has shown that this 
multifunctional protein is involved in a wide variety 
of processes, including regulation of cell prolifera-
tion, cell migration, cell adhesion, cytoskeletal reor-
ganization, and chromosomal stability. Clues to the 
different functions of APC have been provided by 
the identification of proteins interacting with several 
discrete motifs within APC. Each of these putative 
functions could link APC inactivation to cancerogen-
esis (reviewed by: Fodde et al., 2001; van Es et al., 
2001).
Familial adenomatous polyposis (FAP) is 
caused by mutations in the APC gene. More than 
800 mutations in the APC gene have been identi-
fied in families with classic and attenuated types of 
familial adenomatous polyposis. Most of these mu-
tations cause the production of an APC protein that 
is abnormally short and nonfunctional. This short 
protein cannot suppress the cellular overgrowth 
that leads to the formation of polyps, which can 
become cancerous. The most common mutation in 
FAP is a deletion of five bases in the APC gene. 
This mutation changes the sequence of amino ac-
ids in the resulting APC protein beginning at po-
sitions 1309. Additionally, Ile1307Lys, Glu1317Gln, 
Asp1822Val, and other polymorphisms have been 
found. However, these kinds of polymorphism in 
APC gene are regional and population specific and 
are responsible together with environmental factors 
for the risk of colorectal cancer (Friedl et al., 2001; 
Locker et al., 2006; Guerreiro et al., 2007). Also, the 
Ile1307Lys mutation has been found to be clearly 
associated with a somatic additional adenine inser-
tion in the region of codons 1306–1309, but other 
mutations in the region of codons 1277–1348 were 
found to be no more prevalent in carriers than in 
noncarriers (Zauber et al., 2005).
Recently it has been shown that human APC 
protein can interact with the human DNA Pol β-me-
diated one-nucleotide as well as strand-displacement 
synthesis of reduced abasic, nicked-, or 1-nt gapped-
DNA substrates. APC also blocks strand-displace-
ment synthesis of LP-BER and 5'-flap endonuclease 
as well as the 5'→3' exonuclease activity of FEN-1, 
resulting in the blockage of LP-BER. These studies 
will have important implications for understanding 
APC role in DNA damage-induced carcinogenesis 
and chemoprevention, especially critical APC role 
in several cellular processes (Narayan et al., 2005; 
Jaiswal et al., 2006).
Moreover, the fidelity of BER is dependent 
on the polymerization step, where the major BER 
Pol β incorporates nucleotide into the gap. Recent 
studies have indicated that expression of some Pol β 
variants or changes in expression of wild type Pol β 
protein, frequently found in cancer cells, can lead to 
DNA repair synthesis errors and confers to cells a 
mutator phenotype (reviewed by: Chan et al., 2006). 
In this case, it can not be excluded that APC could 
act not only as a factor determining the patch size 
during repair synthesis in BER by Pol β but also as 
a factor limiting the spearing of incorrect incorpora-
tion by Pol β.
BER ENzyMES AS BIOMARKERS IN 
MOLEcuLAR EPIDEMIOLOgy
Oxidative DNA damage and DNA repair me-
diate the development of several human patholo-
gies, including cancer. The major pathway for oxi-
dative DNA damage repair is base excision repair. 
Functional assays performed in blood leukocytes 
of cancer patients and matched controls show that 
specific BER pathways are decreased in cancer pa-
tients, and may be risk factors (Olinski et al., 1998). 
These include 8-oxoguanine (8-oxoG) repair in lung 
and head and neck cancer patients and repair of li-
pid-peroxidation-induced εA in lung cancer patients. 
Decrease of excision of lipid peroxidation-induced 
DNA damage εA and εC was observed in blood 
leukocytes of patients developing lung adenocarci-
noma, a specific histological type of cancer related 
to inflammation and healing of scars (Gackowski et 
al., 2003; Speina et al., 2003; Speina et al., 2005a). The 
activity of BER proteins depends on gene polymor-
phism, interactions among BER system partners, and 
post-translational modifications. Polymorphisms of 
DNA glycosylases may change their enzymatic ac-
tivities, and some polymorphisms increase the risk 
of inflammation-related cancers, colorectal, lung and 
other types.
Alternative splicing of the human OGG1 gene 
produces two major protein isoforms, α-OGG1 and 
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β-OGG1. β-OGG1 is transferred to mitochondria, 
while α-OGG1 is targeted to the nucleus. Both isofor-
ms of human OGG1 exhibit the same catalytic activ-
ity. Several single nucleotide polymorphisms (SNP) 
are present in OGG1 sequence, with Ser326Cys (C→
G in exon 6) being the most frequent. The Cys326 
variant has lower activity than Ser326 and is not 
stimulated by APE1. Since APE1 stimulates excision 
of 8-oxoG from DNA by OGG1, it seems reasonable 
that the activity of 8-oxoguanine DNA glycosylase 
is significantly affected by the Ser326Cys polymor-
phism (Collins & Gaivao, 2007). Therefore, the hu-
man OGG1-Cys326 variant has been proposed to 
increase the risk of lung cancer, prostate cancer, and 
nasopharyngeal carcinoma. Also the rare Arg154His 
(G→T) OGG1 polymorphism has been identified in 
sporadic colorectal cancers but did not segregate 
with cancer phenotypes. Two other less frequent 
OGG1 polymorphisms, Arg46Gln and Arg154His, 
also influence OGG1 activity and were detected in 
human lung and gastric cancers (reviwed by: Nohmi 
et al., 2005).
Alternative splicing of the human MUTYH 
gene produces two major protein isoforms, type 1 
(535 amino acids), which localizes in mitochondria, 
and type 2 (521 amino acids), which is transferred to 
the nucleus. Interestingly, type 2 protein has a high-
er glycosylase activity than type 1 protein. MUTYH 
interacts with a number of proteins, such as RPA, 
APE1, PCNA and MSH6 (Fig. 3), and its expression 
is increased during S phase. Thirty various muta-
tions that are predicted to turncate the protein prod-
uct have been reported in MUTYH gene, comprising 
11 nonsense, 9 small insertion/deletion and 10 splice 
site variants. In addition, 52 missense variants and 3 
small inframe insertion/deletions have been reported 
(reviewed by: Cheadle & Sampson, 2007). Gly382Asp 
and Tyr165Cys substitutions cover more than 70% 
mutations reported in MUTYH gene and are linked 
with higher cancer incidence. The Gly382Asp and 
Tyr165Cys MUTYH variant proteins that are devoid 
of glycosylase activity towards the 8-oxoG : A pair, 
have been found in familial polyposis. These mu-
tations are associated with GC→TA transversions 
in the APC gene. Other MUTYH alterations which 
have been found in patients with colorectal tumors 
are missense Tyr90 or Glu466 to stop codon muta-
tions (reviewed by: Nohmi et al., 2005).
For other components of BER, the association 
of mutations in genes encoding proteins engaged 
in base excision repair with cancerogenesis appears 
less consistent. However, Pol β has been found to 
be overexpressed at both mRNA and protein level 
in about 30% of all tumors studied, with the overex-
pression being particularly frequent in uterus, ova-
ry, prostate and stomach. Pol λ and Pol ι were also 
found to be overexpressed to a significant extent in 
a range of tumor types, albeit less frequently than 
Pol β (Albertella et al., 2005). Additionally, approx. 
30% of human tumors examined for mutations in 
POLB gene appear to express Pol β variant proteins 
(Starcevic et al., 2004). Many of these variants result 
from a single amino-acid substitution. The Lys289Met 
and Ile260Met variants exhibit reduced polymerase 
fidelity and are observed in colon and prostate can-
cer, respectively (Lang et al., 2004; 2007; Sweasy et 
al., 2005). Moreover, the Glu295Lys gastric carcinoma 
Pol β variant acts in a dominant-negative manner by 
interfering with BER, which leads to an increase in 
sister chromatid exchanges and genomic instability 
indicating that BER is critical for maintaining genome 
stability and could therefore be a tumor suppressor 
mechanism (Lang et al., 2007). The Pro242Arg and 
Lys289Met polymorphism of Pol β can be an aux-
iliary marker for breast cancer risk and cancer pro-
gression (Sliwinski et al., 2007). Apart from the sin-
gle substitution, several Pol β cancer-related variants 
were found, e.g. truncation and deletion mutants. The 
wild type and truncated forms of Pol β proteins are 
expressed in primary colorectal and breast adenocar-
cinomas and in a primary culture of renal cell carci-
noma. Three types of deletion variants were detected 
in squamous, non-small, or large cell carcinomas. The 
most common variant was a deletion of 87 bp from 
POLB cDNA at a site corresponding to exon 11. In 
addition, a variant exhibiting deletions of 87 and 140 
bp together with an insertion of 105 bp was identified 
in lung tumors (Bhattacharyya & Banerjee, 1997; Bhat-
tacharyya et al., 1999; Chen et al., 2000; Bhattacharyya 
et al., 2001; Bhattacharyya & Banerjee, 2003). Addi-
tionally, the 208–236 deletion variant found in many 
human tumors has been shown ex vivo to reduce BER 
capacity. Pol β–/– knockout mice are not viable and 
Pol β+/– haploinsufficient mice demonstrate higher 
level of SSBs and increased chromosomal aberrations 
(Cabelof et al., 2003). Also a few SNPs in POLL and 
POLI genes were found, resulting in amino-acid sub-
stitutions within the Pol λ and Pol ι variant proteins, 
respectively. Mutation in POLI has been shown to be 
associated with NSCLC (Sakiyama et al., 2005).
The Arg399Glu (G→A in exon 10) and 
 Arg194Trp (C→T in exon 6) polymorphisms of the 
BER platform protein XRCC1 are connected with 
increased risk of tobacco-related cancers (Santella et 
al., 2005; Shen et al., 2005). In contrast, a lack of as-
sociation of XRCC1 Arg399Gln polymorphism with 
chronic myelogenous leukemia has been observed 
recently (Deligezer et al., 2007). Xrcc1–/– knockout 
mice are not viable (Friedberg & Meira, 2004).
Several amino-acid substitution variants were 
identified in the repair domain of human APE1. 
Functional characterization revealed that the vari-
ants, Leu104Arg, Glu126Asp and Arg237Ala, exhib-
ited approx. 40–60% reductions in specific incision 
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activity. Moreover, the Asp283Gly and Asp283Ala 
variants were found to exhibit approx. 10% repair 
capacity. The most common substitution Asp148Glu 
had no impact on endonuclease and DNA bind-
ing activities, nor did the Gly306Ala substitution. 
The Gly241Arg variant showed a slightly enhanced 
endonuclease activity relative to the wild type. All 
reduced function variants may be associated with 
increased disease susceptibility (Hadi et al., 2000). 
However, a significant association between the 
 Asp148Glu (T→G in exon 5) polymorphism in APE1 
gene and lung cancer risk was found (De Ruyck 
et al., 2007). Ape1–/– knockout mice are not viable 
(Friedberg & Meira, 2004).
Poly(ADP-ribose) polymerase 1 (PARP-1) 
modifies a variety of nuclear proteins by poly(ADP-
ribosyl)ation, and plays diverse roles in molecular 
and cellular processes. PARP-1 is also a platform pro-
tein associated with SSBR and interacts with several 
DNA repair proteins (Fig. 3). The common Val762Ala 
polymorphism of PARP-1 in the catalytic domain is 
implicated in susceptibility to cancer. The PARP-1 
Val762Ala polymorphism reduces the enzymatic ac-
tivity (Wang et al., 2007). PARP-1 deficiency causes 
mammary tumorigenesis in mice underlying the role 
of PARP-1 in suppressing mammary tumorigenesis 
in vivo and suggesting that dysfunction of PARP-1 
may be a risk factor for breast cancer in humans 
(Tong et al., 2007). Recently, all PARP-1 exons, intron-
exon junctions and promoter sequences have been 
sequenced. Rare genetic variants of PARP-1, includ-
ing Ser383Tyr (C→A), Arg452Arg (C→A), Lys940Arg 
(C→G) were detected in about 11% breast cancers. 
Interestingly, the Ala284Ala (T→C) PARP-1 vari-
ant was likely associated with loss of estrogen- and 
progesterone-receptor expression. This implies that 
genetic variants of PARP-1 may contribute to breast 
cancerogenesis and that the PARP-1 Ala284Ala  vari-
ant protein may influence hormonal therapy of breast 
cancer (Cao et al., 2007). Parp-1–/– knockout mice are 
viable. In contrast, double Parp-1–/– Parp-2–/– mice are 
not (Friedberg & Meira, 2004).
BER is also changed in tumors in comparison 
to unaffected surrounding tissues, and this change 
may be due to transcription stimulation, post-trans-
lational modification of BER enzymes as well as 
protein–protein interactions. Modulation of BER en-
zymes’ activities may be, then, an important factor 
determining the risk of cancer and also may partici-
pate in cancer development (Tudek et al., 2006; De 
Ruyck et al., 2007; Tudek, 2007).
SuMMARy
As outlined above, the development of muta-
tor phenotype is proposed to be an early step in car-
cinogenesis. The best known examples of such a situ-
ation are defects in the MUTYH gene which increase 
the G→T transversions in the APC gene in human 
colorectal cancers. Importantly, these mutations are 
frequently formed in hot spots of tumor suppressor 
genes or oncogenes, and thus further influence car-
cinogenesis. DNA-damaging agents may also prefer-
entially modify hot spots of tumor suppressor genes 
or oncogenes. For instance, etheno-adduct-forming 
chemicals, such as vinyl chloride and urethane, have 
been shown to induce specific hot spot mutational 
patterns in TP53 (Kowalczyk et al., 2006) and Ha-ras 
in liver, lung or skin cancers in humans (occupation-
ally exposed to vinyl chloride), rats, and mice (re-
viewed by: Barbin, 2000). Individual susceptibility is 
an important factor in cancer development that de-
pends on carcinogen uptake, balance between meta-
bolic activation and detoxification, DNA repair ac-
tivity, and varying effects of genes involved in DNA 
repair, signal transduction pathways and regulation 
of the cell cycle.
Polymorphisms in genes encoding DNA re-
pair functions can lead to varying capacities of de-
fense against endogenous and environmental DNA 
damaging agents. Since variations in DNA repair 
genes may influence and modulate an individual’s 
cancer susceptibility, screening for polymorphisms 
has become recently a promising area of research in 
molecular epidemiology. Moreover, this knowledge 
is necessary to allow a number of DNA repair in-
hibitors as potential anticarcinogenic compounds. 
However, the ability of the DNA repair inhibitors to 
prevent cancer development is difficult to interpret 
and is sure to depend upon the system used and the 
type of genotoxic stress.
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